Levent Oner (Levent Öner)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 7

Top Topics

Top Venues

Turkish journal of chemistry

Journal of drug targeting

Pharmaceutical development and technology

This page only lists publications with an associated author ORCID identifier.

Publications

Aslıhan Arslan, Barbaros Yet, Emirhan Nemutlu, Yagmur Akdag, Hakan Eroğlu, Levent Oner
Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation. Pharmaceutics 15 (2) (2023)
Aslıhan Arslan, Barbaros Yet, Emirhan Nemutlu, Yagmur Akdag, Hakan Eroğlu, Levent Oner
Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation. Pharmaceutics 15 (2) (2023)
Aslıhan Arslan, Barbaros Yet, Emirhan Nemutlu, Yagmur Akdag, Hakan Eroğlu, Levent Oner
Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation. Pharmaceutics 15 (2) (2023)
Aslıhan Arslan, Barbaros Yet, Emirhan Nemutlu, Yagmur Akdag, Hakan Eroğlu, Levent Oner
Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation. Pharmaceutics 15 (2) (2023)
Esra DemİrtÜrk, Emirhan Nemutlu, Selma Şahİn, Levent Oner
Development and validation of an HPLC method for determination of rofecoxib in bovine serum albumin microspheres. Turkish journal of chemistry 44 (3) (2020)
Tugba Gulsun, Yagmur Akdag, Nihan Izat, Meltem Cetin, Levent Oner, Selma Şahİn
Development and characterization of metformin hydrochloride- and glyburide-containing orally disintegrating tablets. Pharmaceutical development and technology 25 (8) (2020)
Gizem Tezel, Selin Seda Timur, Filiz Kuralay, R Neslihan Gürsoy, Kezban Ulubayram, Levent Oner, Hakan Eroğlu
Current status of micro/nanomotors in drug delivery. Journal of drug targeting 29 (1) (2020)